Debt-to-equity of SUTRO BIOPHARMA, INC. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
SUTRO BIOPHARMA, INC. quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • SUTRO BIOPHARMA, INC. Debt-to-equity for the quarter ending 30 Sep 2025 was -1274%, a 599% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

SUTRO BIOPHARMA, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -1274% -1529% -599% 30 Sep 2025
Q2 2025 1353% +1103% +440% 30 Jun 2025
Q1 2025 485% +241% +99% 31 Mar 2025
Q4 2024 326% +140% +75% 31 Dec 2024
Q3 2024 255% +107% +72% 30 Sep 2024
Q2 2024 250% +143% +134% 30 Jun 2024
Q1 2024 244% +160% +189% 31 Mar 2024
Q4 2023 187% +116% +163% 31 Dec 2023
Q3 2023 148% +91% +160% 30 Sep 2023
Q2 2023 107% +62% +137% 30 Jun 2023
Q1 2023 84% +55% +188% 31 Mar 2023
Q4 2022 71% +47% +191% 31 Dec 2022
Q3 2022 57% +36% +177% 30 Sep 2022
Q2 2022 45% +26% +136% 30 Jun 2022
Q1 2022 29% +7% +29% 31 Mar 2022
Q4 2021 24% -7% -21% 31 Dec 2021
Q3 2021 21% -21% -51% 30 Sep 2021
Q2 2021 19% -34% -64% 30 Jun 2021
Q1 2021 23% -41% -65% 31 Mar 2021
Q4 2020 31% -26% -46% 31 Dec 2020
Q3 2020 42% -18% -30% 30 Sep 2020
Q2 2020 53% -85% -62% 30 Jun 2020
Q1 2020 64% 31 Mar 2020
Q4 2019 57% 31 Dec 2019
Q3 2019 60% 30 Sep 2019
Q2 2019 138% 30 Jun 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.